Our Mission

riluzole

The mission of SciOpen Research Group (SRG) is to promote and facilitate research bridging basic scientific research to investigational therapeutics for amyotrophic lateral sclerosis (ALS). ALS is an invariably fatal disease for which no FDA approved treatment is currently regarded as effective at changing short or long term patient outcomes, to include slowing progression, reversing symptoms, or effectively curing a patient. SRG will identify novel molecular entities with qualities applicable to ALS and will fund further development with the aim of delivering them into human clinical trial. Furthermore, the results of work we fund will be published in Open Access medical journals and public databases so that others may benefit from it.

Home of the world's first fully-functional guerrilla biotech